US 11,944,602 B2
Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Eric Legangneux, Levallois-Perret (FR); Alexandros Sagkriotis, Basel (CH); Pierre Jordaan, Bettingen (CH); Florine Polus, Basel (CH); Alan John Camm, London (GB); Shibadas Biswal, Nucleos North Tower (SG); Parasar Pal, Rangareddy (IN); Uday Kiran Veldandi, Rangareddy (IN); Atul Keshav Pawar, Navi Mumbai (IN); Vassilios Aslanis, Basel (CH); and Kasra Shakeri-Nejad, Basel (CH)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Mar. 23, 2021, as Appl. No. 17/209,940.
Application 17/209,940 is a continuation of application No. 16/684,170, filed on Nov. 14, 2019, abandoned.
Application 16/684,170 is a continuation of application No. 16/058,404, filed on Aug. 8, 2018, abandoned.
Application 16/058,404 is a continuation of application No. 15/552,886, abandoned, previously published as PCT/IB2016/051004, filed on Feb. 24, 2016.
Claims priority of application No. 559/DEL/2015 (IN), filed on Feb. 26, 2015.
Prior Publication US 2022/0008385 A1, Jan. 13, 2022
Int. Cl. A61K 31/397 (2006.01); A61K 9/20 (2006.01); A61K 31/138 (2006.01); A61K 45/06 (2006.01); A61P 37/00 (2006.01)
CPC A61K 31/397 (2013.01) [A61K 9/2018 (2013.01); A61K 31/138 (2013.01); A61K 45/06 (2013.01); A61P 37/00 (2018.01)] 43 Claims
OG exemplary drawing
 
1. A method of treating an autoimmune disease in a patient comprising
a) administering to said patient an initial titration regimen of siponimod;
b) administering to said patient 1-15 mg siponimod daily as a maintenance regimen; and
c) introducing in said patient a beta-blocker treatment the earliest at the first day when said patient is receiving the dosage of the maintenance regimen;
wherein said initial titration regimen comprises administering siponimod at a dosage lower than the dosage of the maintenance regimen and then increasing the dosage stepwise up to the dosage of the maintenance regimen.